Abstract:

Objective To investigate the clinical significance of evolocumab in patients with incomplete revascularization of multi ⁃vessel coronary artery disease complicated with hyperlipidemia. Methods The data of 128 patients with incomplete revascularization of multi⁃vessel coronary artery disease complicated with hyperlipid⁃ emia were retrospectively analyzed. Sixty⁃two patients received evolocumab therapy（the treatment group）and sixty ⁃six patients received conventional therapy（the control group）. All patients were followed up for 3 months. The total cholesterol，triglyceride，low⁃density lipoprotein cholesterol（LDL⁃C），LDL⁃C control rate，Seattle Angina Ques⁃ tionnaire（SAQ）were compared before treatment and 3 months after treatment between the two groups. Results Three months after treatment，the total cholesterol，triglyceride，LDL⁃C after treatment in study group were signifi⁃ cantly lower than those in the control group（P < 0.05），the LDL ⁃C control rate after treatment in the treatment group，and scores of 4 dimensions（stable state of angina pectoris，attack of angina pectoris，physical limitation， treatment satisfaction）in SAQ were significantly higher than those in the control group（P < 0.05）. Conclusions Evolocumab could rapidly change the level of blood lipid in patients with incomplete revascularization of multi ⁃ vessel coronary artery disease complicated with hyperlipidemia，significantly improve in the LDL ⁃C control rate， and could significantly relieve the angina symptoms. 

Key words:

evolocumab, multi?vessel coronary artery disease, hyperlipidemia, incomplete revascu-larization